According to WHO, 8.2 million people die each year from Cancer, which is estimated to be 13% of all deaths globally. There is growing incidence of cancer in Asia-Pacific region. According to WHO, in India, in 2012, around 537000 women and 477000 men were diagnosed with cancer.
The rising use of cancer biomarkers for diagnostic purpose, preference towards non-invasive technologies, increasing government and private initiatives for biomarker discovery and rise in healthcare expenditure are propelling the growth of the market as key drivers. However, high cost of diagnostic procedures and unfavorable regulatory and reimbursement policies are turning out to be restraints for this market.
The Asia-Pacific biomarkers market have been segmented based on disease, applications, services, type and profiling technologies. The segmentation by disease have been subdivided into prostate cancer, breast cancer, lung cancer, colorectal cancer, cervical cancer and others. The segmentation based on applications have been subdivided into risk assessment, development of molecular diagnostics, disease diagnosis, drug discovery and development and drug formulation. The segmentation based on services have been subdivided into sample preparation, assay development and biomarkers validation. The segmentation based on type have been subdivided into protein biomarkers, genetic biomarkers and others (cell, Viral and Carbohydrate biomarkers).The Segmentation based on profiling technologies have been subdivided into Omics Technologies, imaging technologies, Immunoassays, cytogenetics, bioinformatics, and IVD multivariate index assays. The sub-segment on omics technologies include genomics, proteomics, metabolomics, transcriptomics, and pharmacogenomics. The sun-segment on immunoassay includes immunohistochemical (IHC) tests and flow cytometry.
The Asia-Pacific cancer biomarkers market have been geographically segmented into China, India, Japan, South Korea, Australia and New Zealand. The Asia-Pacific market is expected to grow at a fast pace with consistent economic development, increasing growth in healthcare facility, and rising prevalence of cancer. The Major Players in this cancer biomarkers market are Abbott Laboratories, Agilent Technologies, Bio-Rad Laboratories, EKF Diagnostics Holding, Merck and Co. Takeda Pharmaceuticals, Hologic Inc., PerkinElmer, Roche Diagnostics Corporation, BioMerieux, Cisbio bioassay, and Celera Corporation.
Key deliverables of the study:
Market Definition for the specified topic along with identification of key drivers and restraints for the market.
Market analysis for the Asia-Pacific Cancer biomarkers Market, with region specific assessments and competition analysis on regional scale.
Identification of factors instrumental in changing the market scenarios, rising prospective opportunities and identification of key companies which can influence the market in Asia-Pacific.
Extensively researched competitive landscape section with profiles of major companies along with their strategic initiatives and market shares.
Identification and analysis of the Macro and Micro factors that affect the Asia-Pacific Cancer Biomarkers Market on regional scale.
A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.
1.1 Study deliverables
1.2 Market Definition
1.3 Sizing Units
1.4 Base Currency
1.5 Review and Forecast period years
1.6 General Study Assumptions
2. Research Methodology
2.2 Analysis Methodology
2.3 Econometric Forecast Model
2.4 Research Assumptions
3. Executive Summary
4. Key Inferences
5. Market Overview and Industry trends
5.1 Current Market Senario
5.2 Cancer Biomarkers Applications
5.3 Technology Overview
5.4 New Developments
5.5 Industry Value chain analysis
5.6 Product Life cycle analysis
5.7 Product Benchmarking
5.8 Investment Analysis
5.9 Porter's Five Forces
5.9.1 Bargaining Power of Suppliers
5.9.2 Bargaining Power of Consumers
5.9.3 Threat to new entrants
5.9.4 Threat to substitute products and services
5.9.5 Competitive Rivalry within the industry
6. Market Drivers, Restraints, Opportunities, and challenges Analysis
6.1 Market Drivers
6.1.1 Rising use of cancer biomarkers for diagnostic purpose
6.1.2 Preference towards non-invasive technologies
6.1.3 Increasing government and private initiatives for biomarker discovery
6.1.4 Rise in Healthcare expenditure
6.2 Market Restraints
6.2.1 High cost of diagnostic procedures
6.2.2 Unfavorable regulatory and reimbursement system
6.3.1 Potential market in emerging economies
6.3.2 Increasing prevalence of Cancer
6.3.3 Personalized medicine
7. Asia-Pacific Biomarkers Market segmentation
7.1 By Disease
7.1.1 Prostate cancer
7.1.2 Breast cancer
7.1.3 Lung cancer
7.1.4 Colorectal cancer
7.1.5 Cervical Cancer
7.2 By Applications
7.2.1 Risk Assesment
7.2.2 Devlopment of molecular diagnostics
7.2.3 Disese diagnosis
7.2.4 Drug discovery and development
7.2.5 Drug formulation
7.3 By Services
7.3.1 Sample preparation
7.3.2 Assay developement
7.3.3 Biomakers validation and testing
7.4 By Type
7.4.1 Protein biomarkers
7.4.2 Genetic biomarkers
7.4.3 Others (Cell, Viral and Carbohydrate biomarkers)
7.5 By profiling technologies
7.5.1 Omics technologies
7.5.2 Imaging technologies
18.104.22.168 Immunohistochemical (IHC) tests
22.214.171.124 Flow cytometry
126.96.36.199 DNA microarrays
7.5.6 IVD multivariate index assays
8. Asia- Pacific Market segmentation by Geography
8.5 Australia and New Zealand
8.6 South Korea
8.7 Rest of Asia Pacific
9. Competitive Landscape
9.1 Merger and acquisition analysis
9.2 New Product Launches
9.3 Agreements, Collaborations and Parterships
10. Key Vendor Analysis
10.1 Abbott Laboratories
10.2 Agilent Technologies
10.3 Bio-Rad Laboratories
10.4 EKF Diagnostics Holdings, Inc
10.5 Merck & Co.
10.6 Takeda Pharmaceuticals
10.7 Hologic Inc.
10.9 Roche Diagnostics Corp
10.11 Cisbio Bioassays
10.12 Celera Corporation (Quest Diagnostics)
11. Analyst outlook for Investment opportunities
12. Future Outlook of the market